Amicus Therapeutics, Inc. $FOLD Shares Acquired by Peregrine Capital Management LLC

Peregrine Capital Management LLC grew its position in Amicus Therapeutics, Inc. (NASDAQ:FOLD) by 11.2% in the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 1,012,100 shares of the biopharmaceutical company’s stock after acquiring an additional 101,592 shares during the quarter. Peregrine Capital Management LLC’s holdings in Amicus Therapeutics were worth $5,799,000 at the end of the most recent reporting period.

Several other large investors have also modified their holdings of the company. Wellington Management Group LLP boosted its holdings in shares of Amicus Therapeutics by 2.6% in the first quarter. Wellington Management Group LLP now owns 29,200,617 shares of the biopharmaceutical company’s stock valued at $238,277,000 after acquiring an additional 738,623 shares during the period. Redmile Group LLC raised its stake in shares of Amicus Therapeutics by 35.1% during the first quarter. Redmile Group LLC now owns 9,533,669 shares of the biopharmaceutical company’s stock worth $77,795,000 after purchasing an additional 2,478,779 shares during the last quarter. Vestal Point Capital LP raised its stake in shares of Amicus Therapeutics by 27.6% during the first quarter. Vestal Point Capital LP now owns 4,275,000 shares of the biopharmaceutical company’s stock worth $34,884,000 after purchasing an additional 925,000 shares during the last quarter. Assenagon Asset Management S.A. raised its stake in shares of Amicus Therapeutics by 641.2% during the second quarter. Assenagon Asset Management S.A. now owns 3,533,854 shares of the biopharmaceutical company’s stock worth $20,249,000 after purchasing an additional 3,057,072 shares during the last quarter. Finally, Nuveen LLC purchased a new stake in shares of Amicus Therapeutics during the first quarter worth approximately $28,741,000.

Amicus Therapeutics Trading Up 2.4%

NASDAQ:FOLD opened at $8.88 on Tuesday. The stock has a fifty day moving average price of $8.05 and a two-hundred day moving average price of $6.95. The stock has a market capitalization of $2.74 billion, a price-to-earnings ratio of -73.99 and a beta of 0.56. The company has a debt-to-equity ratio of 1.92, a quick ratio of 2.29 and a current ratio of 3.21. Amicus Therapeutics, Inc. has a 1 year low of $5.51 and a 1 year high of $12.65.

Analyst Ratings Changes

FOLD has been the subject of several analyst reports. Needham & Company LLC upgraded Amicus Therapeutics from a “hold” rating to a “buy” rating and set a $14.00 price target for the company in a research note on Thursday, September 18th. Zacks Research upgraded Amicus Therapeutics from a “hold” rating to a “strong-buy” rating in a research note on Monday, October 6th. Morgan Stanley upgraded Amicus Therapeutics from an “equal weight” rating to an “overweight” rating in a research note on Thursday, July 17th. Weiss Ratings restated a “sell (e+)” rating on shares of Amicus Therapeutics in a research note on Wednesday, October 8th. Finally, Wall Street Zen upgraded Amicus Therapeutics from a “hold” rating to a “buy” rating in a research note on Sunday. One investment analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $15.88.

Amicus Therapeutics Profile

Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset.